Fulgent Genetics (FLGT) Projected to Announce Quarterly Earnings on Thursday

Posted by George Bondi on Jul 28th, 2026

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) is projected to release its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Fulgent Genetics to post earnings of ($0.46) per share and revenue of $94.00 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Fulgent Genetics Price Performance

Shares of FLGT opened at $19.58 on Tuesday. The firm has a market cap of $556.07 million, a P/E ratio of -8.19 and a beta of 0.89. The stock has a 50 day simple moving average of $19.12 and a two-hundred day simple moving average of $19.44. Fulgent Genetics has a 1 year low of $13.46 and a 1 year high of $31.04.

Insider Buying and Selling

In other news, insider Hanlin Gao sold 1,688 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $30,198.32. Following the transaction, the insider owned 990,374 shares in the company, valued at approximately $17,717,790.86. This trade represents a 0.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jian Xie sold 2,146 shares of Fulgent Genetics stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $38,391.94. Following the completion of the transaction, the chief operating officer directly owned 367,605 shares in the company, valued at approximately $6,576,453.45. The trade was a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 5,980 shares of company stock valued at $106,360. Insiders own 36.18% of the company’s stock.

Institutional Investors Weigh In On Fulgent Genetics

Large investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new position in shares of Fulgent Genetics during the fourth quarter valued at about $35,000. Raymond James Financial Inc. bought a new stake in shares of Fulgent Genetics in the second quarter worth about $49,000. Quantbot Technologies LP purchased a new position in Fulgent Genetics during the 3rd quarter valued at about $61,000. Los Angeles Capital Management LLC purchased a new position in Fulgent Genetics during the 4th quarter valued at about $218,000. Finally, Advisors Asset Management Inc. raised its position in Fulgent Genetics by 2,205.7% during the 4th quarter. Advisors Asset Management Inc. now owns 8,485 shares of the company’s stock valued at $223,000 after purchasing an additional 8,117 shares during the last quarter. Institutional investors own 48.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on FLGT shares. Piper Sandler restated a “neutral” rating and issued a $15.00 price objective (down from $30.00) on shares of Fulgent Genetics in a report on Tuesday, May 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fulgent Genetics in a report on Monday, July 6th. Finally, Wall Street Zen upgraded shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 30th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $27.00.

Read Our Latest Stock Report on FLGT

Fulgent Genetics Company Profile

(Get Free Report)

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.